John M. Krall

St. Luke's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gerald E. Hanks

Fox Chase Cancer Center

Miljenko V. Pilepich

UCLA Medical Center

Thomas W. Griffin

WinnMed

William T. Sause

Intermountain Healthcare

Karen Martz

Emmes (United States)

George E. Laramore

University of Washington

Sucha O. Asbell

Thomas Jefferson University

Kenneth Russell

Varian Medical Systems (United States)

Moshe Maor

Reichman University

Carlos A. Perez

University of Chile

Cooperative Institutions

RTOG Foundation

American College of Radiology

The University of Texas MD Anderson Cancer Center

Fox Chase Cancer Center

West Virginia University

University of Washington

Radiation Oncology Associates

St. Vincent's Medical Center

University of California, Los Angeles

Wayne State University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Indomethacin for Closure of Patent Ductus Arteriosus in Prematures

Clinical Pediatrics (1982)

Martha D. Mullett Thomas W. Croghan David Z. Myerberg John M. Krall William A. Neal

A controlled, double blind trial of indomethacin versus placebo was conducted in prematures of birth weight <1750 g, with a murmur of patent ductus arteriosus (PDA). The dose of indomethacin was 0.2 mg/kg for 2 doses, orally, 24 hours apart. Forty-seven patients entered the trial. Twenty-four received indomethacin and 12 of these met the criteria for response; 23 received the placebo and two met the criteria for response (p < 0.01). Subsequent surgical ligation for symptomatic PDA was required in 13 of 23 in the placebo group and 4 of 24 in the indomethacin group (p < 0.01). When administered early, indomethacin is moderately effective in closing PDA in premature infants.

Ductus arteriosus

Placebo group

10.1177/000992288202100404

Cite

Citations (27)

Influence of a sampling review process for radiation oncology quality assurance in cooperative group clinical trials — results of the Radiation Therapy Oncology Group (RTOG) analysis

Radiotherapy and Oncology (1995)

Linda Martin John M. Krall Walter J. Curran Steven A. Leibel James D. Cox

10.1016/0167-8140(95)01533-m

Cite

Citations (14)

Estimation of follow-up period required for a clinical trial closed to accrual